Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018160877) IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD USING AN INTERLEUKIN-2 RECEPTOR ALPHA, BETA-SELECTIVE AGONIST IN COMBINATION WITH ADOPTIVE CELL TRANSFER THERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/160877 International Application No.: PCT/US2018/020514
Publication Date: 07.09.2018 International Filing Date: 01.03.2018
IPC:
A61K 38/00 (2006.01) ,C07K 14/435 (2006.01) ,C07K 19/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
19
Hybrid peptides
Applicants:
NEKTAR THERAPEUTICS [US/US]; 455 Mission Bay Boulevard South Suite 100 San Francisco, CA 94158, US
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; US
Inventors:
CHARYCH, Deborah, H.; US
RIBAS, Antoni; US
PARISI, Giulia; US
Agent:
EVANS, Susan, T.; US
WILSON, Mark, A.; US
Priority Data:
62/465,50601.03.2017US
62/480,97103.04.2017US
Title (EN) IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD USING AN INTERLEUKIN-2 RECEPTOR ALPHA, BETA-SELECTIVE AGONIST IN COMBINATION WITH ADOPTIVE CELL TRANSFER THERAPY
(FR) MÉTHODE DE TRAITEMENT IMMUNOTHÉRAPEUTIQUE DE TUMEURS UTILISANT UN AGONISTE ALPHA, BÊTA-SÉLECTIF DU RÉCEPTEUR DE L'INTERLEUKINE-2 EN COMBINAISON AVEC UNE THÉRAPIE PAR TRANSFERT CELLULAIRE ADOPTIF
Abstract:
(EN) Provided are methods and compositions directed towards the treatment of an individual having cancer by providing adoptive cell transfer therapy and administering to the individual a long acting IL-2Rαβ-biased agonist.
(FR) L'invention concerne des méthodes et des compositions dirigées vers le traitement d'un individu atteint d'un cancer en fournissant une thérapie par transfert cellulaire adoptif et en administrant à l'individu un agoniste biaisé pour IL -2 Rαβ à action prolongée.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)